# A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

> **NCT05612633** · PHASE2 · WITHDRAWN · sponsor: **Samus Therapeutics, Inc.**

## Conditions studied

- Accelerated Phase MPN
- Blast Phase MPN

## Interventions

- **DRUG:** zelavespib

## Key facts

- **NCT ID:** NCT05612633
- **Lead sponsor:** Samus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-15
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-02-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Samus Therapeutics Closure
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05612633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05612633, "A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05612633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*